Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 TCR gene therapy for leukemia
ISRCTN11622375Phase 2Completed
- Sponsor
- University College London
- Start
- Jan 2010
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label trial of WT1-specific TCR-transduced autologous T cells in acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) (2 arms), sponsored by University College London. Primary endpoints: Transduction efficiency, Toxicity and side effects and 1 more. Started Jan 2010; status: completed.
02
Drugs
WT1-specific TCR-transduced autologous T cells
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN11622375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11622375.